BIO, the world’s largest biotechnology gathering, is underway in San Diego. Over the meeting’s four days, BIO participants will gain insights from thought leaders and network with colleagues and potential collaborators.
This afternoon at BIO, I will be part of a panel of experts—including Dr. Francis Collins, director of the National Institutes of Health (NIH)—discussing the Accelerating Medicines Partnership or AMP, which was established earlier this year. AMP is a collaboration among the NIH, several nonprofit organizations, and 10 biopharmaceutical companies, including Lilly.
AMP’s goal: To transform the way we identify and validate promising biological targets of disease. The ultimate goal is to increase the number of diagnostics and medicines available to patients and reduce the time and cost of developing them.
Deciphering diseases, gaining a better understanding of the biological basis of human disease, is one of the biggest hurdles we face when bringing new medicines to patients. This is especially true in complicated diseases such as Alzheimer’s disease, type 2 diabetes, andautoimmune disorders. That’s why AMP’s initial projects will be in these disease areas.
Although biopharmaceutical companies are competitors from a business perspective, we share a determination to explore scientific advances for the benefit of patients. We also realize that many biomedical challenges are too complex to solve alone. We need to join forces to better help patients.
Data and analyses generated to decipher disease will be considered precompetitive. AMP’s work won’t use proprietary pre-existing intellectual property, nor do we expect it to yield patentable findings.
Lilly is proud to be a leader in public-private partnerships, such as AMP. We are committed to bringing great minds together to help solve tough biomedical challenges, accelerating breakthroughs for patients who need them, and increasing the efficiency and cost-effectiveness of bringing new medicines to patients.